Loading search results…

Scholars @ Weill Cornell Medicine

Help & supportPhase 1 prototype

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research325

Loading search results…

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research325

FiltersClear all

Status

Recruiting89
Not yet recruiting1
Enrolling by invitation4
Active, not recruiting109
Completed89
Terminated33

Study type

Interventional325

Phase

Phase 3325
Not reported1,641
Not applicable304
Phase 2286
Phase 1103
Phase 1/277

Investigator

Sonal Kumar13
Manish A Shah10
Alpana P. Shukla9
Parag Goyal9
Aliza B Solomon8

Show all 50Show fewer

Department

Medicine204
Pediatrics45
Obstetrics and Gynecology16
Neurology15
Radiation Oncology12

Show all 17Show fewer

Condition

Breast Neoplasms17
Obesity15
COVID-1912
Overweight12
Crohn Disease11

Show all 50Show fewer

Intervention type

Drug288
Biological54
Other53
Procedure37
Radiation25
Device11

Sponsor type

Industry246
Other academic41
NIH16
WCM (investigator-initiated)11
Cooperative group10
Unknown1

Start date

Has results posted108

Phase 3×Clear all

Showing 1–20 of 325 studiesSort:

Active, not recruitingInterventional · Phase 3NCT01901094 ↗
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Eleni AndreopoulouPI
Intervention
Procedure: Axillary Lymph Node Dissection (ALND) · Radiation: Nodal Radiation Therapy · Radiation: Axillary Radiation Therapy
Dates

FiltersClear all

Status

Recruiting89
Not yet recruiting1
Enrolling by invitation4
Active, not recruiting109
Completed89
Terminated33

Study type

Interventional325

Phase

Phase 3325
Not reported1,641
Not applicable304
Phase 2286
Phase 1103
Phase 1/277

Investigator

Sonal Kumar13
Manish A Shah10
Alpana P. Shukla9
Parag Goyal9
Aliza B Solomon8

Show all 50Show fewer

Department

Medicine204
Pediatrics45
Obstetrics and Gynecology16
Neurology15
Radiation Oncology12

Show all 17Show fewer

Condition

Breast Neoplasms17
Obesity15
COVID-1912
Overweight12
Crohn Disease11

Show all 50Show fewer

Intervention type

Drug288
Biological54
Other53
Procedure37
Radiation25
Device11

Sponsor type

Industry246
Other academic41
NIH16
WCM (investigator-initiated)11
Cooperative group10
Unknown1

Start date

Has results posted108

Phase 3×Clear all

Showing 1–20 of 325 studiesSort:

Active, not recruitingInterventional · Phase 3NCT01901094 ↗
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Eleni AndreopoulouPI
Intervention
Procedure: Axillary Lymph Node Dissection (ALND) · Radiation: Nodal Radiation Therapy · Radiation: Axillary Radiation Therapy
Dates

Phase 4

Phase 2/338

Early phase 13

Alexander Ja-Ho Chou7

Catherine McGuinn7

Daniel W Skupski7

Eleni Andreopoulou7

Hani Lamie Ashamalla7

Massimo Cristofanilli7

Felice H Schnoll-Sussman3

Silvia Chiara Formenti3

Georgiana Alina Dobri3

Joseph M Scandura3

Jia Ruan3

Lok W. Yung3

Maria Teresa DeSancho3

Matthew William McCarthy3

Catherine Butkus Small2

Cardiothoracic Surgery4

Neurological Surgery4

Rehabilitation Medicine2

Anesthesiology1

Ophthalmology1

Otolaryngology Head and Neck Surgery1

Prostatic Neoplasms

Neoplasm Metastasis8

Colitis, Ulcerative7

Leukemia, Myeloid, Acute7

Lung Diseases, Interstitial7

Multiple Myeloma7

Carcinoma, Non-Small-Cell Lung6

Cardiovascular Diseases6

Hemophilia A6

Hypertension, Pulmonary6

Myelodysplastic Syndromes6

Non-alcoholic Fatty Liver Disease6

Atrial Fibrillation5

Liver Cirrhosis, Biliary5

Neoplasms5

Parkinson Disease5

Parkinson Disease 4, Autosomal Dominant Lewy Body5

Pulmonary Arterial Hypertension5

Pulmonary Disease, Chronic Obstructive5

Coronavirus Infections4

Dermatitis, Atopic4

Idiopathic Pulmonary Fibrosis4

Lung Neoplasms4

Metabolic Diseases4

Ovarian Neoplasms4

Adenocarcinoma Of Esophagus3

Diabetes Mellitus, Type 23

Digestive System Diseases3

Endocrine System Diseases3

Eosinophilic Esophagitis3

Esophageal Squamous Cell Carcinoma3

Fallopian Tube Neoplasms3

Hematologic Neoplasms3

Hypertension3

Inflammatory Bowel Diseases3

Combination product

Feb 2014 – Jan 2031 (est.)

Sponsor

Alliance for Clinical Trials in Oncology

Stage II Breast CancerStage IIIA Breast Cancer

Active, not recruitingInterventional · Phase 3NCT02193282 ↗

Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

Ashish SaxenaPI

Intervention: Other: Clinical Observation · Drug: Erlotinib Hydrochloride · Other: Laboratory Biomarker Analysis · Other: Placebo Administration
Dates: Feb 2015 – Dec 2025
Sponsor: Alliance for Clinical Trials in Oncology

Lung Non-Squamous Non-Small Cell CarcinomaStage IB Lung Non-Small Cell Carcinoma AJCC v7Stage II Lung Non-Small Cell Cancer AJCC v7+3 more

RecruitingInterventional · Phase 3NCT02582697 ↗

Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours

Alexander Ja-Ho ChouPI

Intervention: Drug: Bleomycin (active name: Bleomycin Sulfate) · Drug: Etoposide · Drug: Cisplatin · Drug: Pegylated G-CSF (Pegfilgrastim) · Drug: Filgrastim
Dates: Feb 2014 – Dec 2029 (est.)
Sponsor: Children's Oncology Group

Germ Cell Tumor

Active, not recruitingInterventional · Phase 3NCT02954874 ↗

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy

Eleni AndreopoulouPI

Intervention: Procedure: Biospecimen Collection · Other: Laboratory Biomarker Analysis · Other: Patient Observation · Biological: Pembrolizumab · Other: Quality-of-Life Assessment · Other: Questionnaire Administration · Radiation: Radiation Therapy
Dates: Jan 2017 – Aug 2026
Sponsor: Southwest Oncology Group

Breast Carcinoma In SituInvasive Breast CarcinomaStage I Breast Cancer AJCC v7+3 more

Active, not recruitingInterventional · Phase 3NCT03105102 ↗

A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects With Crohn's Disease

Aliza B SolomonPI

Intervention: Drug: Placebo for Risankizumab SC · Drug: Risankizumab IV · Drug: Placebo for Risankizumab IV · Drug: Risankizumab SC · Drug: Risankizumab On-Body Injector (OBI)
Dates: Apr 2018 – Feb 2029 (est.)
Sponsor: AbbVie Inc.

Crohn's Disease

Active, not recruitingInterventional · Phase 3NCT03301506 ↗

ASSURE: An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)

Sonal KumarPI

Intervention: Drug: Seladelpar 5 mg Capsule · Drug: Seladelpar 10 mg Capsule
Dates: Dec 2017 – Nov 2028 (est.)
Sponsor: Gilead Sciences, Inc.

Primary Biliary Cirrhosis

Active, not recruitingInterventional · Phase 3NCT03488693 ↗

TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

Hani Lamie AshamallaPI

Intervention: Radiation: Radiation · Other: No Radiation
Dates: Oct 2018 – Sep 2027 (est.)
Sponsor: Canadian Cancer Trials Group

Breast Cancer

Active, not recruitingInterventional · Phase 3NCT03533582 ↗

Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)

Alexander Ja-Ho ChouPI

Intervention: Procedure: Biospecimen Collection · Drug: Carboplatin · Drug: Cisplatin · Drug: Doxorubicin · Drug: Etoposide · Drug: Fluorouracil · Drug: Gemcitabine · Drug: Irinotecan · Drug: Oxaliplatin · Other: Patient Observation · Procedure: Resection · Drug: Sorafenib · Drug: Vincristine Sulfate
Dates: May 2018 – Mar 2027 (est.)
Sponsor: Children's Oncology Group

Childhood Hepatocellular CarcinomaChildhood Malignant Liver NeoplasmFibrolamellar Carcinoma+2 more

Active, not recruitingInterventional · Phase 3NCT03568383 ↗

Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx MDR-TB)

Jean W. PapePI

Intervention: Drug: Delamanid (DLM) · Drug: Isoniazid (INH) · Dietary supplement: Pyridoxine (vitamin B6)
Dates: Jun 2019 – Nov 2026 (est.)
Sponsor: National Institute of Allergy & Infectious Diseases

Tuberculosis, MDR

Active, not recruitingInterventional · Phase 3NCT03602859 ↗

A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

Eloise ChapmanPI

Intervention: Drug: Niraparib · Drug: Dostarlimab (TSR-042) · Drug: Standard of care · Drug: Dostarlimab-Placebo · Drug: Niraparib-Placebo
Dates: Oct 2018 – Oct 2024· Results posted
Sponsor: Tesaro, Inc.

Ovarian NeoplasmsOvarian, Fallopian Tube and Primary Peritoneal Carcinoma

Active, not recruitingInterventional · Phase 3NCT03653507 ↗

A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Manish A ShahPI

Intervention: Drug: zolbetuximab · Drug: oxaliplatin · Drug: capecitabine · Drug: placebo
Dates: Nov 2018 – Oct 2022· Results posted
Sponsor: Astellas Pharma Global Development, Inc.

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more

RecruitingInterventional · Phase 3NCT03678025 ↗

Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

Douglas S ScherrPI

Intervention: Drug: Abiraterone · Drug: Bicalutamide · Drug: Degarelix · Drug: Docetaxel · Drug: Flutamide · Drug: Goserelin Acetate · Drug: Histrelin Acetate · Drug: Leuprolide Acetate · Drug: Nilutamide · Procedure: Orchiectomy · Drug: Prednisone · Other: Quality-of-Life Assessment · Radiation: Radiation Therapy · Procedure: Radical Prostatectomy · Drug: Triptorelin
Dates: Sep 2018 – Apr 2033 (est.)
Sponsor: Southwest Oncology Group

Castration Levels of TestosteroneMetastatic Prostatic AdenocarcinomaStage IV Prostate Cancer AJCC v8+2 more

Active, not recruitingInterventional · Phase 3NCT03682068 ↗

A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination With Standard of Care Chemotherapy and Durvalumab in Combination With Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients With Unresectable Locally Advanced or Metastatic Urothelial Cancer.

Scott T. TagawaPI

Intervention: Drug: Durvalumab · Drug: Tremelimumab · Drug: Cisplatin + Gemcitabine · Drug: Carboplatin + Gemcitabine
Dates: Sep 2018 – Jun 2026
Sponsor: AstraZeneca Pharmaceuticals LP

Unresectable Locally Advanced Urothelial CancerMetastatic Urothelial Cancer

Enrolling by invitationInterventional · Phase 3NCT03683186 ↗

A Phase 3 Open-label Extension (OLE) Study to Evaluate the Long-term Safety and Efficacy of Ralinepag in Subjects With World Health Organization (WHO) Group 1 Pulmonary Arterial Hypertension (PAH)

Evelyn M. HornPI

Intervention: Drug: Ralinepag
Dates: Sep 2019 – Dec 2026 (est.)
Sponsor: United Therapeutics

PAHPulmonary HypertensionPulmonary Arterial Hypertension+8 more

Active, not recruitingInterventional · Phase 3NCT03725059 ↗

A Randomized, Double-Blind, Phase III Study of Pembrolizumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (KEYNOTE-756)

Eleni AndreopoulouPI

Intervention: Biological: Pembrolizumab (K) · Drug: Placebo (P) · Drug: Paclitaxel (X) · Drug: Doxorubicin (A) · Drug: Epirubicin (E) · Drug: Cyclophosphamide (C) · Drug: Endocrine therapy · Radiation: Radiation therapy · Procedure: Surgery
Dates: Dec 2018 – Jan 2031 (est.)
Sponsor: Merck & Co., Inc.

Breast Cancer

Active, not recruitingInterventional · Phase 3NCT03737981 ↗

A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)

John AllanPI

Intervention: Drug: Ibrutinib · Biological: Obinutuzumab · Other: Observation Activity · Drug: Venetoclax
Dates: Jan 2019 – Jan 2025· Results posted
Sponsor: Alliance for Clinical Trials in Oncology

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma

Active, not recruitingInterventional · Phase 3NCT03765918 ↗

A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)

Doru PaulPI

Intervention: Biological: Pembrolizumab 200 mg · Radiation: Radiotherapy 60 Gray · Radiation: Radiotherapy 66 Gray · Radiation: Radiotherapy 70 Gray · Drug: Cisplatin 100 mg/m^2
Dates: Dec 2018 – Jul 2024· Results posted
Sponsor: Merck Sharp & Dohme Corp

Head and Neck Neoplasms

Active, not recruitingInterventional · Phase 3NCT03767244 ↗

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

Jim C. HuPI

Intervention: Drug: Apalutamide · Drug: Androgen Deprivation Therapy (ADT) · Drug: Placebo
Dates: Jun 2019 – Dec 2026 (est.)
Sponsor: Janssen Research & Development, LLC

Prostatic Neoplasms

Active, not recruitingInterventional · Phase 3NCT03793166 ↗

PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]

Ana M. MolinaPI

Intervention: Procedure: Biospecimen Collection · Procedure: Bone Scan · Drug: Cabozantinib · Procedure: Computed Tomography · Biological: Ipilimumab · Procedure: Magnetic Resonance Imaging · Biological: Nivolumab · Other: Quality-of-Life Assessment · Other: Questionnaire Administration
Dates: Jun 2019 – Mar 2028 (est.)
Sponsor: Alliance for Clinical Trials in Oncology

Clear Cell Renal Cell CarcinomaMetastatic Malignant Neoplasm in the BoneMetastatic Malignant Neoplasm in the Lymph Nodes+6 more

Active, not recruitingInterventional · Phase 3NCT03803553 ↗

Early Identification and Treatment of Occult Metastatic Disease in Stage III Colon Cancer

Manish A ShahPI

Intervention: Drug: FOLFIRI Protocol · Other: ACTIVE SURVEILLANCE · Drug: Nivolumab Protocol · Drug: Encorafenib/Binimetinib/Cetuximab Protocol · Drug: Trastuzumab + Pertuzumab
Dates: Apr 2020 – Dec 2026 (est.)
Sponsor: The General Hospital Corporation (dba Massachusetts General Hospital)

Metastatic Colon CancerStage III Colon Cancer

‹ Prev1 2 3 4 5…13 14 15 16 17 Next ›